The Irving Cancer Drug Discovery Program (ICDDP) is designed to provide the critical infrastructure and support needed to enable the development of key scientific discoveries into new approaches for the diagnosis and treatment of cancers. The program will support a range of projects including the development of diverse therapeutic modalities such as small molecules, antibodies (biologics), and cell therapies, as well as the development of new computational, diagnostic, and drug delivery technologies. Projects at any stage of development, from target validation and high throughput screening to preclinical testing and IND enabling studies, will be supported. The Cancer Drug Discovery Program will work with HICCC Accelerator ACT and Columbia Technology Ventures to help completed projects partner with external entities for further clinical development.
Applications are open to full-time Columbia Faculty. Letter of intent due Feb. 15. Full proposal due March 15. Apply here.